Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabetic Kidney Disease (DKD)
- Main trialPhase 2
- “This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times”In the company’s words, NCT07271186 on ClinicalTrials.gov
Other drugs for Diabetic Kidney Disease (DKD)
- WAL0921Walden Biosciences · Phase 2
- R3R01River 3 Renal Corp. · Phase 2
- IsuzinaxibAptabio Therapeutics, Inc. · Phase 2
- Umbilical Cord Mesenchymal Stem CellsPT. Prodia Stem Cell Indonesia · Phase 1/2
- EvinacumabRegeneron · Phase 2
- AtrasentanNovartis · Phase 2
Coming up2
- 4 DecPhase 1 trial completes · ClinicalTrials.gov
- 13 Oct 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 13 Oct 2028 | Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease | |
| Phase 1Active, not recruiting | 4 Dec 2026 | A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026